Browsing Tag
Novartis
87 posts
CHMP recommends approval for BeiGene’s tislelizumab in ESCC treatment
BeiGene, a global biotechnology firm, has revealed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
Novartis acquires biotech firm DTx Pharma to gain access to FALCON platform
Swiss pharmaceutical giant Novartis has acquired DTx Pharma, a preclinical stage biotechnology company based in California renowned for…
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast…
Aurobindo subsidiary gets license to develop and market Nilotinib Capsules in LMICs
Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent…
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington…
Novartis to offload US rights to five ophthalmic drugs to Harrow
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products…
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted…
Dr. Reddy’s to sell and distribute certain Novartis’ products in India
Dr. Reddy’s Laboratories has signed an exclusive sales and distribution agreement with Novartis India Limited (NIL) for the…
Novartis to acquire ocular gene therapy company Gyroscope Therapeutics
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up…
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA)…